Raymond James Financial Services Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $482K | Buy |
6,864
+336
| +5% | +$28.1K | ﹤0.01% | 2647 |
|
|
2024
Q2 | $537K | Sell |
6,528
-885
| -12% | -$73.7K | ﹤0.01% | 2485 |
|
|
2024
Q1 | $647K | Buy |
7,413
+72
| +1% | +$6.45K | ﹤0.01% | 2333 |
|
|
2023
Q4 | $708K | Sell |
7,341
-14,508
| -66% | -$1.28M | ﹤0.01% | 2184 |
|
|
2023
Q3 | $1.93M | Buy |
21,849
+2,232
| +11% | +$199K | ﹤0.01% | 1521 |
|
|
2023
Q2 | $1.7M | Sell |
19,617
-3,288
| -14% | -$309K | ﹤0.01% | 1608 |
|
|
2023
Q1 | $2.23M | Buy |
22,905
+8,620
| +60% | +$894K | ﹤0.01% | 1425 |
|
|
2022
Q4 | $1.48M | Sell |
14,285
-955
| -6% | -$89.7K | ﹤0.01% | 1612 |
|
|
2022
Q3 | $1.29M | Buy |
15,240
+863
| +6% | +$76.8K | ﹤0.01% | 1677 |
|
|
2022
Q2 | $1.19M | Sell |
14,377
-2,461
| -15% | -$196K | ﹤0.01% | 1724 |
|
|
2022
Q1 | $1.3M | Buy |
16,838
+11,672
| +226% | +$977K | ﹤0.01% | 1773 |
|
|
2021
Q4 | $456K | Sell |
5,166
-5,068
| -50% | -$418K | ﹤0.01% | 2437 |
|
|
2021
Q3 | $791K | Sell |
10,234
-2,324
| -19% | -$183K | ﹤0.01% | 2112 |
|
|
2021
Q2 | $1.05M | Buy |
12,558
+4,765
| +61% | +$378K | ﹤0.01% | 1918 |
|
|
2021
Q1 | $588K | Buy |
7,793
+2,425
| +45% | +$198K | ﹤0.01% | 2182 |
|
|
2020
Q4 | $471K | Buy |
5,368
+1,120
| +26% | +$88.8K | ﹤0.01% | 2174 |
|
|
2020
Q3 | $323K | Sell |
4,248
-30
| -0.7% | -$3.04K | ﹤0.01% | 2235 |
|
|
2020
Q2 | $528K | Buy |
+4,278
| New | +$425K | ﹤0.01% | 1894 |
|
|
2020
Q1 | – | Sell |
-4,765
| Closed | -$403K | – | 2450 |
|
|
2019
Q4 | $403K | Buy |
+4,765
| New | +$360K | ﹤0.01% | 2117 |
|
|
2019
Q3 | – | Sell |
-2,400
| Closed | -$206K | – | 2831 |
|
|
2019
Q2 | $206K | Sell |
2,400
-925
| -28% | -$79.1K | ﹤0.01% | 2525 |
|
|
2019
Q1 | $295K | Buy |
3,325
+582
| +21% | +$53.9K | ﹤0.01% | 2250 |
|
|
2018
Q4 | $234K | Sell |
2,743
-725
| -21% | -$69K | ﹤0.01% | 2155 |
|
|
2018
Q3 | $336K | Buy |
3,468
+842
| +32% | +$84K | ﹤0.01% | 2202 |
|
|
2018
Q2 | $247K | Sell |
2,626
-497
| -16% | -$43.5K | ﹤0.01% | 2365 |
|
|
2018
Q1 | $253K | Buy |
3,123
+606
| +24% | +$52K | ﹤0.01% | 2130 |
|
|
2017
Q4 | $224K | Buy |
+2,517
| New | +$219K | ﹤0.01% | 2184 |
|
|
2017
Q2 | – | Sell |
-11,288
| Closed | -$1.03M | – | 2523 |
|
|
2017
Q1 | $991K | Buy |
11,288
+7,461
| +195% | +$664K | 0.01% | 1193 |
|
|
2016
Q4 | $317K | Sell |
3,827
-3,958
| -51% | -$340K | ﹤0.01% | 1781 |
|
|
2016
Q3 | $720K | Sell |
7,785
-4,225
| -35% | -$398K | 0.01% | 1285 |
|
|
2016
Q2 | $934K | Buy |
12,010
+7,096
| +144% | +$603K | 0.01% | 1080 |
|
|
2016
Q1 | $405K | Buy |
+4,914
| New | +$400K | ﹤0.01% | 1368 |
|
Other funds holding BMRN
EIM
Raymond James Financial Services Advisors's BMRN Position: Q3 2024 in Review
Raymond James Financial Services Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 5.1% in Q3 2024, buying an estimated $28.1K and bringing the position to 6,864 shares worth $482K. The position accounts for ﹤0.01% of the portfolio, ranked #2647.
Raymond James Financial Services Advisors first reported a position in BMRN in Q1 2016 and has held it in 31 quarters since. The position peaked at $2.23M in Q1 2023. 554 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.
- Raymond James Financial Services Advisors held 6,864 shares of BioMarin Pharmaceuticals worth $482K as of Q3 2024.
- Raymond James Financial Services Advisors bought 336 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $28.1K.
- BioMarin Pharmaceuticals made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #2647 holding.
- Raymond James Financial Services Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2016 and has held it in 31 quarters since.
- Raymond James Financial Services Advisors's BioMarin Pharmaceuticals position peaked at $2.23M in Q1 2023.
- 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.
Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.